anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:A safe inhibitor of blood platelet aggregation having improved inhibitory action on blood platelet aggregation and extremely low toxicity, containing a specific compound extracted from seeds of Trichosanthes kirillowii MSXIMOWICZ var. japonicum KITAMURA, a cucurbitaceous plant as an active ingredient. CONSTITUTION:An inhibitor of blood platelet aggregation containing a compound shown by the formula I [R is H or group shown by the formula II (A is linoleoyl or oleoyl; B is tricosanoyl, linoleoyl or oleoyl)] as an active ingredient. 1,3-Ditricosanoyl-2-linoleoyl-glycerol (R = group shown by formula I and A is linoleoyl; B is tricosanoyl) among the compound shown by the formula I is obtained by extracting seeds of Trichosanthes kirillowii MAXIMOWICZ var. japonicum KITAMURA with water, methanol, etc., taking it partially by column chromatography, preparative liquid chromatography or high performance liquid chromatography and further hydrolyzed into tricosanoic acid where R=H. The inhibitor has excellent medicinal effect and safety.
In this arm, patients are adviced on reading the customised website. This arm is compared to Arm 3.
The present invention provides calixpyrrole, calixpyridinopyrrole, and calixpyridine macrocycles, having 4, 5, 6, 7, or 8 heterocyclic rings, as well as syntheses, derivatives. conjugates, multimers, and solid supports thereof. Such macrocycles have proved to be effective and selective ion- and neutral molecule-binding agents forming supramolecular ensembles, and ion- and neutral molecule-separation agents. The macrocycles are fully meso-non-hydrogen-substituted porphyrinogens, a few molecules of which were previously known but not recognized as possessing anion- or molecule-binding properties. The binding mode is noncovalent, primarily that of hydrogen-bonding, thereby providing a new mode for liquid chromatography, that of Hydrogen Bonding Liquid Chromatography. Further useful applications of the macrocycles provided herein include environmental remediation by removal of undesired ions or neutral molecules, and removal of phosphate for kidney dialysis.
FIELD: organic chemistry, chemical technology. SUBSTANCE: invention relates to new derivatives of quinolone carboxylic acid of the formula (I)  , their pharmaceutically acceptable salts and hydrates where X means hydrocarbon group, fluorocarbon group or nitrogen atom; Y means hydrogen atom or methyl group; R 1  means hydrogen atom or C 1 -C 5 -alkyl group; R 2  means a group of the formula (a)   where A and B mean fluorocarbon group or nitrogen atom at condition that when A is CF then B is N and when A is N then B is CF; R 3  means a group of the formula (b)   where substitute R 4  means amino-group with racemate or (S)-enantiomer formation, or a group of the formula (c)   where substituents R 5 , R 6  and R 7  mean hydrogen atom or C 1 -C 3 -alkyl group. Derivative of quinolone carboxylic acid of the formula (I) is synthesized by condensation of compound of the formula (II)   and compound of the formula HR 3  in solvent in the presence of acid acceptor and excess of compound of the formula HR 3  that is one of reagents. Solvent is taken from a group involving pyridine, acetonitrile, N,N-dimethylformamide. In compound of the formula (II) and compound of the formula HR 3  substituents X, Y, Z, R 1 , R 2  and R 3  mean values indicated above. EFFECT: improved method of synthesis. 11 cl, 6 tbl, 29 ex
A method of coating an article is provided. The method includes: preparing a solution including a bioactive agent and a carbon nanotube precursor; treating the solution to form carbon nanotubes; and applying the solution to the article. A method of producing a medical device is provided. The method includes: forming a core of the medical device with a pattern on a surface of the core and assembling a multi-walled carbon nanotube array on the pattern on the surface. The pattern on the surface may determine an orientation of the multi-walled carbon nanotube array. A method of manufacturing a medical appliance is provided. The method includes creating a mixture of a carbon nanotube precursor and a polymer and injecting the mixture into a mold. The mold forms the mixture into a shape of the medical appliance. A method of forming a nanotube tissue scaffold is provided. The method includes forming a nanotube precursor and treating the nanotube precursor to form the nanotube tissue scaffold. The nanotube tissue scaffold is electrically conductive.
Patients receive vinorelbine tartrate IV over 6-10 minutes on days 1 and 8 and cyclophosphamide IV over 30-60 minutes on day 1. Patients also receive bevacizumab IV over 30-90 minutes on day 1.
Methods of reducing cystine containing animal and plant proteins, and improving dough and baked goods' characteristics is provided which includes the steps of mixing dough with a thiol redox protein. The method of the present invention preferably uses reduced thioredoxin with wheat flour. Methods for reducing snake, bee and scorpion toxin proteins with a thiol redox (SH) agent and thereby inactivating the protein are also provided. Protease inhibitors are also reduced by the NADP/thioredoxin system. When two of these inhibitors, the Kunitz and Bowman-Birk trypsin inhibitors of soybean are reduced, they lose their ability to inhibit trypsin. Moreover, the reduced form of the inhibitors showed increased susceptibility to heat and proteolysis by either subtilisin or a protease preparation from germinating wheat seeds. A novel cystine containing protein that inhibits pullulanase was isolated. When it was reduced by thioredoxin its inhibitory activity was reduced.
Locally advanced rectal cancer has traditionally been treated with multimodal therapy including neoadjuvant chemoradiotherapy followed by surgical resection. More recent data suggests that in appropriate patients, total neoadjuvant treatment (TNT) makes it possible to adopt a "watch and wait" approach. Advocates for watch and wait argue that patients with a complete or near-complete clinical response to TNT have comparable overall and disease-free survival to their counterparts who undergo surgical resection, and also have a better quality of life, fewer complications, and potentially avoid a stoma. The dogma of surgery as regional curative intent therapy has been challenged by similar recurrence rates among those treated with total mesorectal excision (TME) and those treated with watch and wait. Furthermore, those who develop local recurrence in the watch and wait groups are equally salvageable, either by surgery, brachytherapy, or chemotherapy. While watch and wait is not appropriate in all patients, this manuscript highlights the benefits and drawbacks of both therapeutic modalities.
The present invention relates to a preparation technology and a production method for an integrated new formulation of a turtle shell decocted pill, wherein the raw materials of active ingredients comprise: 12 parts by weight of turtle shell, 3 parts by weight of blackberrylily rhizome, 3 parts by weight of radix scutellariae, 6 parts by weight of radix bupleuri, 3 parts by weight of pillbug, 3 parts by weight of dry ginger, 3 parts by weight of rheum officinale, etc. The production process of the turtle shell decocted pill comprises the following steps of: supersonic air-jet crushing, alcohol-water extraction, ultrasonic crushing extraction, water decocting concentration, supersonic spray drying, nanometer grinding, high pressure homogenization, nano particle preparation and the like. According to the invention, the advantages, such as multi-synergism, multi-target, embodied by a nano-carrier coupling technique, are focused to be taken of. After the integrated new formulation of turtle shell decocted pill is subjected to scale production, the production cost can be greatly reduced, the quality of products is greatly improved and the targeting property, and the sustained and controlled release performance of the medicament are enhanced. The internal and external administration of the integrated new formulation of turtle shell decocted pill can be realized simultaneously, and the medicament can be separately taken in four time slices according to the midnight-noon ebb-flow and qi and the blood flowing rule of a human body. The integrated new formulation of turtle shell decocted pill can be further prepared into films and transdermal agents, which are respectively stuck to different parts of a human body according to the midnight-noon ebb-flow and qi and blood flowing rule of the human body, and can be directly absorbed through skin.
INTRODUCTION: The pathogenesis of Post-Transplant Diabetes Mellitus (PTDM) is complex and multifactorial and it resembles that of Type-2 Diabetes Mellitus (T2DM). One risk factor specific to PTDM differentiates both entities: the use of immunosuppressive therapy. Specifically, Tacrolimus interacts with obesity and insulin resistance (IR) in accelerating the onset of PTDM. In a genotypic model of IR, the obese Zucker rats, Tacrolimus is highly diabetogenic by promoting the same changes in beta-cell already modified by IR. Nevertheless, genotypic animal models have their limitations and may not resemble the real pathophysiology of diabetes. In this study, we have evaluated the interaction between beta-cell damage and Tacrolimus in a non-genotypic animal model of obesity and metabolic syndrome.
METHODS: Sprague Dawley rats were fed a high-fat enriched diet during 45 days to induce obesity and metabolic dysregulation. On top of this established obesity, the administration of Tacrolimus (1mg/kg/day) during 15 days induced severe hyperglycaemia and changes in morphological and structural characteristics of the pancreas.
RESULTS: Obese animals administered with Tacrolimus showed increased size of islets of Langerhans and reduced beta-cell proliferation without changes in apoptosis. There were also changes in beta-cell nuclear factors such as a decrease in nuclear expression of MafA and a nuclear overexpression of FoxO1A, PDX-1 and NeuroD1. These animals also showed increased levels of pancreatic insulin and glucagon.
DISCUSSION: This model could be evidence of the relationship between the T2DM and PTDM physiopathology and, eventually, the model may be instrumental to study the pathogenesis of T2DM.
Currently, regional anesthesia techniques for total hip arthroplasty are limited. Fascia iliac blocks have been employed to provide analgesia for hip surgeries with blockade of the femoral, lateral femoral cutaneous, and obturator nerves via injection of local anesthetic in the iliacus fascia. In addition, lumbar plexus blocks have also been employed for post-operative analgesia, but the complexity of the block is high, and complications including epidural anesthesia are not infrequent. The quadratus lumborum block is an abdominal truncal block in which local anesthetic is deposited into the thoracolumbar fascia or the quadratus lumborum muscle itself with the goal of providing analgesia to the ipsilateral T6 - L1 sensory dermatomes. It has already been demonstrated to provide effective post-operative analgesia for certain abdominal and pelvic surgeries, but its use in total hip arthroplasty is limited to case reports.

The block is accomplished by identifying the quadratus lumborum muscle, which originates from iliac crest and iliolumbar ligament, and inserted on transverse processes of upper four lumbar vertebrae and posterior border of the 12th rib. Local anesthetic is then deposited at the anterior, posterior or middle thoracolumbar fascia, or intramuscularly, depending on the technique used. Cadaveric studies8 have demonstrated dye spread to the lumbar nerve roots and nerves within the transversus abdominis plane (TAP). Carney et al9 described a "posterior TAP" block, now known to be synonymous with QLB, that demonstrated contrast spread to the thoracic paravertebral space from T5-L1. Case reports have described analgesia in the corresponding sensory dermatomes after QLB4, and have demonstrated efficacy in patient undergoing THA. The QLB block has potential to cover lateral femoral cutaneous nerve, femoral nerve, obturator nerve and portions of lumbar plexus.

This study has been designed to investigate the efficacy of the quadratus lumborum block as a primary method of providing post-operative analgesia in patients undergoing THA. Previous trials have demonstrated the effectiveness of the block for abdominal and pelvic surgeries, and case reports have shown its applicability in hip arthroplasty. In this randomized controlled study we aim to compare QLB (intervention) with control (no intervention) group in patients undergoing THA with regard to the VAS pain scores (at PACU arrival \& discharge12, 24 \& 36 hours), duration of analgesia, time to first opioid medication, physical therapy evaluations, time to discharge, and surgeon and patient satisfaction scores.
The dosage of metoprolol tartrate tablets should be individualized. Metoprolol tartrate tablets should be taken with or immediately following meals.

The usual initial dosage of metoprolol tartrate tablets is 100 mg daily, given in two divided doses. Gradually increase the dosage at weekly intervals until optimum clinical response has been obtained or there is pronounced slowing of the heart rate. The effective dosage range of metoprolol tartrate tablets is 100 mg to 400 mg per day. Dosages above 400 mg per day have not been studied. If treatment is to be discontinued, gradually decrease the dosage over a period of 1 to 2 weeks (see WARNINGS).
The invention discloses a basic fibroblast growth factor composition, which is prepared from the following components in percentage by mass: 0.01-0.05% of basic fibroblast growth factor, 1.2-3% of mannitol, 0.05-0.2% of hyaluronic acid, 0.01-0.2% of tea polyphenol and the balance of first purified water. The invention also provides a preparation method of the basic fibroblast growth factor composition. The invention also provides a hair restorer. The invention also provides two preparation methods of the hair restorer. The invention also provides a using method of the hair restorer. The basic fibroblast growth factor in the composition can stimulate and promote the differentiation of hair follicle stem cells, prevent the atrophy and degeneration of hair follicle cells, has a repairing function on the degenerated and atrophic hair follicle cells, gradually improves the microenvironment for the growth of the root of hair, and ensures that the hair roots have sufficient nutrition supply and grow normally.
Patients undergo 32 minute treatments twice daily for 12 weeks using the FlexiTouch Plus System and treatment with a lymphedema therapist weekly on weeks 2-11. Patients undergo nasolaryngoscopy and videofluoroscopic swallow study at baseline.
Participants receive four 1-hour group motivational interviewing sessions focused on reducing substance use and sexual risk behavior. They also receive an HIV information brochure and Community Resource Guide.
The administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentration. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentration.

Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there is sodium retention with edema.

Solutions containing potassium ions should be used with great care, if at all, in patients with hyperkalemia, severe renal failure, and in conditions in which potassium retention is present.

In patients with diminished renal function, administration of solutions containing sodium or potassium ions may result in sodium or potassium retention.

Infuse solutions containing phosphate slowly to avoid phosphate intoxication. Infusing high concentrations of phosphate may cause hypocalcemia and tetany. Serum phosphorus and calcium levels should be monitored frequently.

Solutions containing acetate should be used with great care in patients with metabolic or respiratory alkalosis. The administration of acetate should be done with great care in those conditions in which there is an increased level or an impaired utilization of acetate, such as severe hepatic insufficiency.
Early luteal phase Controlled ovarian hyperstimulation: we will administer in the 13th-15th cycle day simultaneously 0.25 mg/day of ganirelix to induce luteolysis and FSHr (dose according to BMI and AFC )IU/day for controlled ovarian hyperstimulation until achieving criteria for hCG , to induce final oocyte maturation. Mature oocytes will be vitrified. After warming, oocytes will be inseminated by ICSI with the recipients partners semen sample . Recipient endometrium will be primed with estrogen and progesterone , and embryo transfer will be performed on the 3rd day 3 of embryo cleavage.
Understanding the molecular mechanisms underlying genetic diseases is challenging due to environmental and genetic factors. Genome-wide association studies (GWAS) have identified numerous genetic loci, but their functional implications are largely unknown. Single-cell multiomics sequencing has emerged as a powerful tool to study disease-specific cell types and their relationship with genetic variants. However, comprehensive databases for exploring these mechanisms across different tissues are lacking. We present the Disease-Related Cell Type database (DRCTdb), integrating GWAS and single-cell multiomics data to identify disease-related cell types and elucidate their regulatory mechanisms. DRCTdb contains well-processed data from 16 studies, covering 4 million cells within 28 tissues. Users can browse relationships and regulatory mechanisms between SNPs of 42 genetic diseases and cell types based on GWAS and single-cell data. DRCTdb also offers data downloads and is available at https://singlecellatlas.top/DRCTDB .
Cohort 1 will consist of 12 subjects (6 AMG 557: 6 placebo) randomized to receive AMG 557 210 mg or matching placebo. Cohort 2 will consist of 12 subjects (6 AMG 557: 6 placebo) randomized to receive AMG 557 140 mg or matching placebo. Enrollment of Cohort 2 (140 mg) will be initiated after enrollment of Cohort 1 (210 mg) is completed. After Cohort 1 and 2 enrollment has been completed, the emerging PK and PD data will be reviewed to determine if an additional 4-8 subjects with SCLE will be enrolled into the study to address equivocal results from the study. These 4-8 additional subjects will receive the same dose of either 210 mg or 140 mg SC (in an allocation ratio of 1 AMG 557: 1 placebo).

In addition, an open label extension study for participants in this study may be instituted following completion and analysis of results of this study. Initiation of this study will require that an acceptable risk-benefit profile and some evidence of efficacy are observed in the current study.
Lung cancer is one of the most significant malignancies, with both high morbidity and mortality. CDK10 is closely related to cancer progression and metastasis. However, its role in lung cancer radioresistance demands further clarification. In this study, we demonstrated that CDK10 was downregulated in lung cancer tissues, and CDK10 expression level was associated with the clinical prognosis in lung cancer patients. We also found that silencing CDK10 promoted lung cancer cell proliferation, migration, and radioresistance. We further verified that silencing CDK10 facilitated the activation of JNK/c-Jun signaling, and c-Jun depletion could reverse the effects of CDK10 knockdown in lung cancer cells. Our findings revealed that CDK10 plays an important role in cell growth and radioresistance by inhibiting JNK/c-Jun signaling pathway in lung cancer. Therefore, CDK10 might be a promising therapeutic target in lung cancer. [BMB Reports 2024; 57(7): 336-341].
Participants will complete seven modules (each approximately 15 minutes) over seven weeks. The purpose of VACT-CP is to assist with at home therapeutic and behavioral self-management of chronic pain, based on the principles of acceptance and commitment therapy. Following the end of treatment (7 weeks), participants will complete post-treatment surveys at Week 7, Month 3, and Month 6 to provide feedback and information regarding 1) the intervention and 2) the potential impact of the intervention on functioning, quality of life, and other mental and physical health factors.
The present invention provides a method for preparing chondrocytes which enable construction of a cartilage tissue, the method being capable of solving the problems with conventional methods.  A method for preparing chondrocytes, comprising co-culturing chondrogenic cells with vascular cells. A composition for cartilage regenerative therapy, comprising chondrocytes prepared by the above-described method. A method of screening for drugs effective as pharmaceuticals, comprising using chondrocytes prepared by the above-described method, a cartilage tissue formed from the chondrocytes and/or cells derived from the cartilage tissue. A method for preparing a matrix produced by chondrocytes, comprising using chondrocytes prepared by the above-described method, a cartilage tissue formed from the chondrocytes and/or cells derived from the cartilage tissue. A method for cartilage regeneration, comprising transplanting chondrocytes prepared by the above-described method into an organism to form a cartilage tissue.
Intervention for intraoperative analgesic administration will be based on heart rate and blood pressure variations. Intervention for intraoperative hypnotice/desflurane administration will based on keeping the MAC at 0.8.
INTRODUCTION: The lifetime prevalence of human papillomavirus infection (HPV) is estimated to be around 80% and it is the most common sexually transmitted infection. Despite being well known for its oncologic relevance, it has been associated with adverse pregnancy outcomes, though available evidence is contradicting. Previous meta-analyses involved articles which based HPV infection on Pap smear results, leading to a significant source of bias. Therefore, we aimed to assess the burden of genetically proven HPV infection on adverse pregnancy outcomes.
MATERIAL AND METHODS: In our meta-analysis, pregnant women tested for HPV DNA were only considered eligible. We conducted a systematic search in three major databases (PubMed, Embase, and CENTRAL) on September 22, 2023. Cohort, cross-sectional, and case-control studies were eligible for the analysis. The exposed group consisted of HPV-infected patients. We assessed the odds ratios (OR) with a confidence interval (CI) of 95%. In order to reduce the heterogeneity, we performed subgroup analyses based on different strains (high risk HPV, HPV 16/18, study design). The study was prospectively registered on PROSPERO (CRD42022370228).
RESULTS: Our study involved 14 articles with 7008 women. A significant association was found between preterm delivery and HPV infection (OR: 1.94, CI: 1.31-2.87). No significant association was found when separately examining high-risk HPV-infected women (OR: 1.94, CI: 0.82-4.59), and HPV 16 or 18-infected women (OR: 2.08, CI: 0.50-8.63) in terms of preterm delivery. No significant association was found between spontaneous abortion and HPV infection (OR: 1.02, CI: 0.16-6.31).
CONCLUSIONS: Our analysis indicates an association between HPV infection and preterm delivery. It is imperative that future studies consider confounding variables more comprehensively. Additionally, the global implementation of HPV vaccination programs holds significance not only in oncology but also in obstetrics.